OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	36
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	30
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	30
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	26
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	25
Learning pharmacometric covariate model structures with symbolic regression networks	22
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	22
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	16
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	16
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	16
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	15
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	15
Current practices for QSP model assessment: an IQ consortium survey	15
Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis	14
ADPO: automatic-differentiation-assisted parametric optimization	14
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	14
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	13
Training the next generation of pharmacometric modelers: a multisector perspective	12
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	12
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	11
Informatics for toxicokinetics	11
Imputation of missing clock times – application to procalcitonin concentration time course after birth	11
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	10
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	10
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	10

Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	9
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	9
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	9
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	9
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	8
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	8
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I data	8
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Scoping review of the role of pharmacometrics in model-informed drug development	8
Uncertainty undermines the validity of antimicrobial pharmacodynamics	8
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8
Thanks to our Reviewers of 2022!	7
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	7
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	7
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	7
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	7
An automated pipeline to generate initial estimates for population Pharmacokinetic base models	7
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	7
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	7
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	7
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	6
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	6
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	6
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model	6
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer’s Disease: A mixed-effects disease progression model	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	6
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	6
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	6